| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
05-21-2013, 11:59 AM
|
#1 | ||
|
|||
|
Member
|
Additional analysis of the study results identified a more robust response to CERE-120 in Parkinson's patients diagnosed within 5 years prior to treatment relative to those diagnosed 10 years or more (p<.005), as measured by change from baseline on the Unified Parkinson's Disease Rating Scale or (UPDRS) motor-off, the primary endpoint for this study.
This makes sense although they didn't say where it leaves them with CERE-120 for future research......... http://prn.to/12JClVz |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Ceregene CERE-120 | Parkinson's Disease | |||
| Opexa reports additional favorable data with Tovaxin for MS | Multiple Sclerosis | |||
| May2009: Ceregene Presents Additional Clinical Data Phase 2 Trial of CERE-120 for PD | Parkinson's Disease | |||
| CERE-120 /May2009/ Clinical Data from Phase 2 Trial of CERE-120 for PD | Parkinson's Disease Clinical Trials | |||
| Ceregene is updating Cere 120 | Parkinson's Disease Clinical Trials | |||
For what it's worth - Ceregene Reports Additional Efficacy Data on CERE-120
Linear Mode
